Antimicrobial peptides have been studied for decades as resistance-proof antibiotics, and the gap between in vitro potency and clinical utility explains the slow translation.
Key Takeaways
- Most act on microbial membranes through electrostatic attraction followed by disruption, which is structurally harder for bacteria to resist than a specific enzyme target.
- Activity measured in low-salt broth frequently collapses at physiological ionic strength and in the presence of serum proteins.
- Work has shifted toward engineered analogues with improved selectivity, synergy with conventional antibiotics, and anti-biofilm applications.
The mechanistic appeal
Most act on microbial membranes through electrostatic attraction followed by disruption, which is structurally harder for bacteria to resist than a specific enzyme target. This is the core argument for their potential durability against resistance.
Selectivity is the hard part
The same cationic amphipathic character that attracts them to bacterial membranes also drives interaction with mammalian membranes. Achieving a wide enough therapeutic window has been the persistent obstacle, usually expressed as haemolysis relative to antimicrobial activity.
For related mechanism work, see phage display peptide libraries.
Salt and serum sensitivity in vivo
Activity measured in low-salt broth frequently collapses at physiological ionic strength and in the presence of serum proteins. This discrepancy accounts for much of the translational disappointment in the field.
Where products have succeeded
Approved and clinically used agents tend to be topical or locally administered rather than systemic, which sidesteps both the selectivity and the stability problems. This pattern reflects the biology rather than a lack of ambition.
Current directions
Work has shifted toward engineered analogues with improved selectivity, synergy with conventional antibiotics, and anti-biofilm applications. Combining mechanisms looks more promising than trying to raise standalone potency.
Experimental Conditions and Practical Setup
Activity is reported as a minimum inhibitory concentration measured in standardised broth, with a parallel haemolysis assay to derive a selectivity index. The critical addition is a physiological-salt arm and a serum arm, since activity measured only in low-salt broth systematically overstates what the peptide will do in a host.
Readouts for antimicrobial peptide work
| Assay | Reports | Interpretation limit |
|---|---|---|
| Minimum inhibitory concentration | Growth inhibition in broth | Salt and serum sensitive |
| Haemolysis | Mammalian membrane toxicity | Proxy, not tissue tolerance |
| Selectivity index | Ratio of the two | Depends on both assay conditions |
| Biofilm assay | Activity against sessile cells | Much higher concentrations needed |
Practical Notes for the Bench
- Measure activity at physiological salt and in serum, not only in broth.
- Track haemolysis alongside antimicrobial potency as a selectivity index.
- Consider topical or local use where systemic exposure is not required.
Frequently Asked Questions
Why have so few become systemic drugs?
Because selectivity for microbial over mammalian membranes is difficult, and activity drops sharply at physiological salt and in serum.
Is resistance really unlikely?
Membrane-targeting mechanisms are structurally harder to resist than single-enzyme targets, but resistance is not impossible and should not be assumed away.
Where are they used clinically?
Mostly in topical and local applications rather than systemic therapy.
Why do so few become systemic medicines?
Because the therapeutic window is narrow once physiological salt and serum are taken into account, and because systemic tolerability of membrane-active agents is difficult to achieve.
Related Reading
- phage display peptide libraries
- peptide immunogenicity
- peptide blood-brain barrier delivery
- reproducible peptide experiments
- reconstituting lyophilised peptides
References & Further Reading
- Szymczak P et al. AI-Driven Antimicrobial Peptide Discovery: Mining and Generation. Acc Chem Res. 2025. PubMed 40459283
- Mhlongo JT et al. Antimicrobial Peptide Synergies for Fighting Infectious Diseases. Adv Sci (Weinh). 2023. PubMed 37407512
- Yang Y et al. Exosome/antimicrobial peptide laden hydrogel wound dressings promote scarless wound healing through miR-21-5p-mediated multiple functions. Biomaterials. 2024. PubMed 38581764
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- USP general chapters on pharmaceutical analysis
This article summarises published research practice for laboratory professionals. It is not a guide to human use, and no claim of therapeutic benefit is made or implied.
Reviewed by Dr. Elena Marchetti, Peptide Chemistry & Analytical Characterization.